We also discovered the molecular mechanism in which SOX2 binds to the CD39 promoter to regulate eATP level, and evaluated the enhanced immune response by inhibiting CD39 after ADM treatment in a mouse glioma model. This evidence concerns the gene SOX2 and glioma.